These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [The prevalence of secondary resistance to peroral hypoglycemic agents among patients with type-2 diabetes mellitus]. Gendeleka GF; Kuznetsova NP Lik Sprava; 1995; (1-2):103-5. PubMed ID: 7483508 [TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus in the Jamaican elderly. Eldemire D; Hagley K West Indian Med J; 1996 Sep; 45(3):82-4. PubMed ID: 8952427 [TBL] [Abstract][Full Text] [Related]
5. [Agreements and disagreements among the main clinical practice guidelines]. Calderón Montero A Semergen; 2014 Jul; 40 Suppl 2():16-24. PubMed ID: 25311716 [TBL] [Abstract][Full Text] [Related]
6. Oral antidiabetic agents: 2004. Lebovitz HE Med Clin North Am; 2004 Jul; 88(4):847-63, ix-x. PubMed ID: 15308382 [TBL] [Abstract][Full Text] [Related]
7. Insulin therapy in type 2 diabetes. Davis T; Edelman SV Med Clin North Am; 2004 Jul; 88(4):865-95, x. PubMed ID: 15308383 [TBL] [Abstract][Full Text] [Related]
8. Incretin mimetics vie for slice of type 2 diabetes market. Shaffer C Nat Biotechnol; 2007 Mar; 25(3):263. PubMed ID: 17344865 [No Abstract] [Full Text] [Related]
9. Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. Packer M J Diabetes Complications; 2018 Jun; 32(6):616-617. PubMed ID: 29627373 [No Abstract] [Full Text] [Related]
10. Re: Leiter LA, Berard L, Bowering CK, et al. Type 2 Diabetes mellitus management in Canada: is it improving? Can J Diabetes 37;2:82-9. Halperin IJ; Ivers NM; Wong R Can J Diabetes; 2013 Aug; 37(4):213. PubMed ID: 24070882 [No Abstract] [Full Text] [Related]
11. Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults. Pilla SJ; Segal JB; Alexander GC; Boyd CM; Maruthur NM J Am Geriatr Soc; 2019 May; 67(5):1066-1073. PubMed ID: 30703251 [TBL] [Abstract][Full Text] [Related]
12. [Diabetes in 2015: constantly increasing, but with enlarged therapeutics options]. Jornayvaz FR; Philippe J Rev Med Suisse; 2015 Jun; 11(477):1219-20. PubMed ID: 26211280 [No Abstract] [Full Text] [Related]
13. Diabetic dyslipidemia and the heart. Vasudevan AR; Garber AJ Heart Fail Clin; 2006 Jan; 2(1):37-52. PubMed ID: 17386875 [No Abstract] [Full Text] [Related]
14. Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects. Hartman I; Rojas E; RodrÃguez-Molina D Am J Ther; 2013; 20(4):384-93. PubMed ID: 23459193 [TBL] [Abstract][Full Text] [Related]
15. Bone disorders associated with diabetes mellitus and its treatments. Cortet B; Lucas S; Legroux-Gerot I; Penel G; Chauveau C; Paccou J Joint Bone Spine; 2019 May; 86(3):315-320. PubMed ID: 30098423 [TBL] [Abstract][Full Text] [Related]
16. In defence of NICE draft type 2 diabetes guidelines. Beran D; Yudkin JS Lancet Diabetes Endocrinol; 2015 Jun; 3(6):406. PubMed ID: 26003753 [No Abstract] [Full Text] [Related]
17. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755 [TBL] [Abstract][Full Text] [Related]
19. Evidence that patients at diagnosis of type 2 diabetes mellitus in Northern Greece are increasingly younger and more obese during the last years. Symeonidis G; Papanas N; Mavridis G; Maltezos E Acta Diabetol; 2003 Mar; 40(1):1-2. PubMed ID: 12688251 [No Abstract] [Full Text] [Related]
20. Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories. Tsimihodimos V; Gonzalez-Villalpando C; Meigs JB; Ferrannini E Hypertension; 2018 Mar; 71(3):422-428. PubMed ID: 29335249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]